Posted by AGORACOM-JC
at 12:32 PM on Wednesday, June 19th, 2019
SPONSOR: North Bud Farms Inc. (NBUD:CSE) Sustainable low cost, high
quality cannabinoid production and procurement focusing on both
bio-pharmaceutical development and Cannabinoid Infused Products. Learn More.
NBUD: CSE
—————
Feds issue regs on cannabis edibles, beverages, extracts and topicals
• THC content in edibles products will be limited to 10 milligrams per package;
• THC in concentrates and topicals will be limited to 1,000 milligrams;
Edibles, beverages, extracts and topicals – oh my! Health Canada has finally released regulations guiding the production and sale of the next wave of cannabis products entering the legal market.
What we know so far:
• THC content in edibles products will be limited to 10 milligrams per package;
• THC in concentrates and topicals will be limited to 1,000 milligrams;
• Almost all of the products you know and love from the grey market
will be available, from brownies and gummies to shatter and rosin;
• Under the new regs, edible cannabis products cannot be produced in
the same site as other food products nor can they be appealing to
children.
The marketing of these cannabis products will continue to follow
tobacco standards, although the warning labels will be focused more on
harm reduction. Health Canada wants cannabis consumers to “start low and go slow†with so many cannabis products coming onto the market.
While cannabis consumers may hem and haw about the restrictive THC
limit for edibles, restaurant owners across Canada are salivating at the
prospect of finally being legally able to serve cannabis products
regulated by Health Canada, only the federal government does not have
the power to license on-premises sales. That power rests with the
provinces. In Ontario, that would mean both the Ministry of Finance and
the Ministry of the Attorney General handing down that responsibility to
the Alcohol and Gaming Commission of Ontario to create a licensing
regime.
The province has been fairly quiet on the issue of on-premises sales to date.
While the vaping and smoking of cannabis products on premises in
Ontario is prohibited by the Smoke-Free Ontario Act, the only thing
stopping restaurants from serving cannabis products is provincial
licensing.
Ontario Premier Doug Ford has told industry types privately that he would like Ontario to have the most permissive edibles regulations in Canada.
But cannabis smoking lounges seem like a pipe dream, with current
regs prohibiting the sale of booze and cannabis in the same location.
It’s up to the province of Ontario to move forward to allow the sale. Nova Scotia has done it.
But complicating matters is the fact that the Legislature is on
summer recess and won’t be back to the daily business of governing until
late October, which is after the new regs are scheduled to come into
effect October 17.
Without on-premises sales, this leaves a huge grey area for cannabis events, live concerts and edibles dinners.
Many questions remain as to how on-premise sales will roll out across Canada.
Lisa Campbell is CEO of Lifford Cannabis Solutions and co-chair of the Cannabis Beverage Producers Alliance.
Tags: CSE, Hemp, Marijuana, stocks, tsx, tsx-v, weed Posted in All Recent Posts, North Bud Farms Inc | Comments Off on North Bud Farms Inc. $NBUD.ca – Feds issue regs on #cannabis #edibles, beverages, extracts and topicals $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $TRST.ca $OGI.ca
Posted by AGORACOM-JC
at 11:39 AM on Tuesday, June 18th, 2019
Entered into a binding letter of intent to acquire all of the issued and outstanding securities of Tanforan Ventures LLC, a California-based licensed operator holding Category 7 extraction and distribution licenses, in a transaction valued at CAD$8.6Â million
Tanforan holds manufacturing and distribution licenses in the state of California and is in the final stages of completing its new Category 7 licensed extraction facility in Woodland, CaliforniaÂ
TORONTO, June 18, 2019 — North Bud Farms Inc.(CSE: NBUD) (OTCQB: NOBDF) (“NORTHBUD” or the “Company”) is pleased to announce that effective June 15, 2019 it has entered into a binding letter of intent (“LOIâ€) to acquire all of the issued and outstanding securities of Tanforan Ventures LLC (“Tanforanâ€), a California-based licensed operator holding Category 7 extraction and distribution licenses, in a transaction valued at CAD$8.6 million. Â
Tanforan holds manufacturing and distribution licenses in the state
of California and is in the final stages of completing its new Category 7
licensed extraction facility in Woodland, California.
“We are very excited to have the opportunity to secure additional
infrastructure and talent as we continue to execute on our U.S.
expansion plans,†said Ryan Brown, CEO of North Bud Farms. “This
strategically located extraction facility will facilitate the
transportation of crude extract derived from bio-mass grown at contract
farms located in Northern California. Assuming the successful closing of
the proposed transaction with Tanforan and our previously announced
transaction with Eureka Vapor, we intend to further process the crude
extract into a finished consumer product at Eureka Vapor’s manufacturing
and distribution facility located in Los Angeles to service the
Southern California market.â€
Transaction Terms The
proposed transaction (the “Transactionâ€) is currently structured as a
share purchase agreement whereby in exchange for the purchase of all of
the securities of Tanforan, NORTHBUD will issue CAD$5 million in common
shares (“Common Sharesâ€) to the shareholders of Tanforan (the “Tanforan
Shareholdersâ€) with the price per Common Share to be determined based on
a formula of the higher of (a) CAD$0.35 per Common Share and (b) the
30-day volume weighted average price (“VWAPâ€) calculated on the closing
date (the “Closing Dateâ€) of a definitive agreement in respect of the
Transaction (the “Definitive Agreementâ€). NORTHBUD and Tanforan expect
to enter into the Definitive Agreement by October 1, 2019.
In addition, Tanforan shareholders will be entitled to receive up to
an additional CAD$3.6 million in Common Shares of NORTHBUD, on a pro
rata basis, upon Tanforan achieving revenue of USD$11,700,000 from
extraction contracts over a 12 month period following the closing of the
Transaction. All of the foregoing revenue milestone Common Shares will
have a deemed value equal to the consideration shares and will be
subject to the same escrow period.
10% of the Common Shares to be issued pursuant to the Definitive
Agreement will be issued to the Tanforan shareholders on the Closing
Date, with the remainder of the Common Shares to be issued in equal
tranches after six, twelve, eighteen, and twenty-four months from the
Closing Date (the “Escrow Periodâ€).
The Transaction is a significant acquisition, but will not result in a
“Fundamental Change†pursuant to the policies of the CSE. NORTHBUD will
be preparing the necessary corporate and securities filings in order to
secure the required approvals for the Transaction.
NORTHBUD has agreed to pay $150,000 in broker/finder fees to arm’s
length parties in connection with the closing of the Transaction.
The closing of the Transaction is conditional on Tanforan receiving
its final Certificate of Occupancy from the city of Woodland, the
receipt of all applicable permits as well as the receipt by the parties
of applicable corporate and regulatory approvals including that of the
CSE.
“The opportunity to acquire a state-of-the-art facility with an
experienced operations team is an exciting prospect for NORTHBUD,†says
Ryan Brown, CEO of NORTHBUD. “We believe that the combination of
Tanforan’s facility and services combined with Eureka Vapor’s products
and distribution will give NORTHBUD an excellent platform to capitalize
on the California recreational cannabis market, considered to be the
largest in North America.â€
“The Tanforan team is excited to join forces with NORTHBUD and Eureka
to capitalize on the largest consumer market in North America,†said
Shannan Day, CEO of Tanforan Ventures. “Tanforan has extensive exclusive
agreements with licensed Cannabis farms in Northern California and we
look forward to working with NORTHBUD and Eureka to create high quality
products for distribution in Southern California.â€
While the proposed transactions involving Tanforan and Eureka Vapor
are complementary, they are independent and the Company may ultimately
proceed to close one, both or neither of the proposed transactions,
depending on market conditions and regulatory requirements.
Update on Acquisition of Eureka Vapor As
previously announced in the Company’s press release dated May 15, 2019,
NORTHBUD and Eureka Vapor LLC (“Eurekaâ€) continue to work towards
completing a definitive agreement whereby NORTHBUD is to acquire all of
the issued and outstanding shares of Eureka and all of its subsidiaries.
Based on projected timelines for the completion of the audit of
Eureka’s financial statements, the companies expect to sign a definitive
agreement in the third quarter of the 2019 calendar year.
Update on Financing The Company expects to close
a first tranche of its non-brokered private placement later this week.
As previously announced on May 15, 2019, the private placement is for up
to 13,333,333 units at a price of $0.30 per unit, for gross proceeds of
up to $4 million. Each unit will be comprised of one common share of
the Company and one common share purchase warrant. Each warrant will
entitle the holder to acquire an additional share at a price of $0.40
for a period of 24 months from the closing date.
About Tanforan Ventures LLC. Historically
Tanforan’s business operated under the proposition 215 regulatory
structure. As of January 2019, Tanforan successfully applied for and
received a volatile extraction license under the California adult use
regulations laws. Tanforan specializes in white label extraction
services.
About North Bud Farms Inc. North Bud Farms Inc.,
through its wholly owned subsidiary GrowPros MMP Inc., is pursuing a
licence under The Cannabis Act. The Company is constructing a
state-of-the-art purpose-built cannabis production facility located on
95 acres of Agricultural Land in Low, Quebec. North Bud Farms Inc. will
be focused on Pharmaceutical and Food Grade cannabinoid production in
preparation for the legalization of edibles and ingestible products
scheduled for October 2019.
About Eureka Vapor LLC Headquartered in Los
Angeles, California, EUREKA Vapor was founded in 2011 and holds licenses
in both California and Colorado. EUREKA Vapor’s multi state operation
manufactures and sells a premium line of vaporizer cartridges,
disposable vapor pens and proprietary vaporizer batteries designed to
work with their highly sought-after CO2 extracted oil. Using their
refined extraction processes and techniques developed over almost a
decade of extracting, EUREKA Vapor is committed to providing the
cleanest and safest natural oil cartridges in the industry. Long
referred to as one of the leaders in the industry, EUREKA has one of the
most loyal customer bases in the category which reflects their
commitment to honesty and transparency above all else. EUREKA
continually looks for innovative ways to improve and refine their
product offerings in order to deliver the best, most consistent vaping
experience in the industry.
Neither the Canadian Securities Exchange (the “CSEâ€) nor its
Regulation Services Provider (as that term is defined in the policies of
the CSE) accepts responsibility for the adequacy or accuracy of this
release.
Forward-looking statements Certain statements
included in this press release constitute forward-looking information or
statements (collectively, “forward-looking statementsâ€), including
those identified by the expressions “anticipateâ€, “believeâ€, “planâ€,
“estimateâ€, “expectâ€, “intendâ€, “mayâ€, “should†and similar expressions
to the extent they relate to the Company or its management. The
forward-looking statements are not historical facts but reflect current
expectations regarding future results or events. This press release
contains forward- looking statements including those relating to the
entering into of the Definitive Agreement, closing of the Transaction
and associated approvals, Tanforan’s ability to achieve milestones under
the Definitive Agreement and associated Common Share issuances. These
forward-looking statements are based on current expectations and various
estimates, factors and assumptions and involve known and unknown risks,
uncertainties and other factors. Such risks and uncertainties include,
among others, the risk factors included in North Bud Farms Inc.’s final
long form prospectus dated August 21, 2018 which is available under the
issuer’s SEDAR profile at www.sedar.com.
FOR ADDITIONAL INFORMATION, PLEASE CONTACT: North Bud Farms Inc. Edward Miller VP, IR & Communications Office: (855) 628-3420 ext. 3 [email protected]
Tags: CSE, Hemp, Marijuana, stocks, tsx, tsx-v, weed Posted in All Recent Posts, North Bud Farms Inc | Comments Off on North Bud Farms $NBUD.ca Signs Binding Letter of Intent to Acquire California Licensed Extraction Company Tanforan Ventures $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $TRST.ca $OGI.ca
Posted by AGORACOM-JC
at 8:37 AM on Tuesday, June 18th, 2019
Announced the start of its commercial planting at its hemp farm in Scio, Oregon.
Also in the process of obtaining organic certification
This season’s harvest was more environmentally friendly, with biodegradable plastic mulch brought in from Canada to eliminate the end-of-season environmental waste, thus reducing labor costs associated with its removal from the field.
ESCONDIDO, Calif., June 18, 2019 – MARIJUANA COMPANY OF AMERICA INC.(“MCOA†or the “Companyâ€) (OTCQB: MCOA), an innovative hemp and cannabis corporation, along with joint venture partner Global Hemp Group (CSE: GHG/ OTC: GBHPF/ FRA: GHG), are pleased to announce the start of its commercial planting at its hemp farm in Scio, Oregon.
Marijuana Company of America previously announced its high-yielding
cannabidiol (CBD) hemp farming project with joint venture partner Global
Hemp Group in 2018. The Scio, Oregon, farm, operating under the name
Covered Bridge Acres Ltd. (“CBAâ€), has finished preparing the 35-acre
land for planting, which is now in the process of laying the last of the
mulch and drip line. CBA is also in the process of obtaining organic
certification. This season’s harvest was more environmentally friendly,
with biodegradable plastic mulch brought in from Canada to eliminate the
end-of-season environmental waste, thus reducing labor costs associated
with its removal from the field.
The hemp plants used for this year’s cultivation have been produced
from either sprouted seed or through CBA’s cloning operation that is
done onsite at the Company’s greenhouses fully controlled by the CBA
team. Genetics being used this year are of higher quality and more
stable than those planted last year. The team expects to plant 40,000 to
50,000 plantlets this year, with a CBD content ranging from 12 percent
to 15 percent. Any excess clones not required for the field will be sold
or used for expansion. This year’s cloning operation has eliminated the
need to purchase clones from third parties, as was required last
season. This will reduce operating expenses in the current year by
approximately $200,000.
The CBA team continues to prepare the greenhouses for constant
harvest to produce high-quality, smokeable hemp flower. Trimmed,
high-end flower, with less than 0.3 percent THC, currently wholesales
for 10 times the price of CBD biomass that is going to extraction.
About Global Hemp Group Inc. Global Hemp Group
Inc. (CSE: GHG) (OTC: GBHPF) (FRANKFURT: GHG) is focused on a
multi-phased strategy to build a strong presence in the industrial hemp
industry in both Canada and the United States. The Company is
headquartered in Vancouver, British Columbia, with hemp cultivation
operations in New Brunswick and Oregon. The first phase of this strategy
is to develop hemp cultivation with the objective of extracting
cannabinoids (CBD, CBG, CBN, and CBC) and creating a near-term revenue
stream that will allow the Company to expand and develop successive
phases of the strategy. The second phase of the plan will focus on the
development of value-added industrial hemp products utilizing the
processing of the whole hemp plant, as envisioned in the Company’s Hemp
Agro-Industrial Zone (HAIZ) strategy.
About Marijuana Company of America, Inc. MCOA is a
corporation which participates in: (1) product research and development
of legal hemp-based consumer products under the brand name
“hempSMART™â€, that targets general health and well-being; (2) an
affiliate marketing program to promote and sell its legal hemp-based
consumer products containing CBD; (3) leasing of real property to
separate business entities engaged in the growth and sale of cannabis in
those states and jurisdictions where cannabis has been legalized and
properly regulated for medicinal and recreational use; and, (4) the
expansion of its business into ancillary areas of the legalized cannabis
and hemp industry, as the legalized markets and opportunities in this
segment mature and develop.
About Our hempSMART Products Containing CBD The
United States Food and Drug Administration (FDA) has not recognized CBD
as a safe and effective drug for any indication. Our products containing
CBD derived from industrial hemp are not marketed or sold based upon
claims that their use is safe and effective treatment for any medical
condition as drugs or dietary supplements subject to the FDA’s
jurisdiction.
Forward-looking Statements This news
release contains “forward-looking statements” which are not purely
historical and may include any statements regarding beliefs, plans,
expectations or intentions regarding the future. Such forward-looking
statements include, among other things, the development, costs and
results of new business opportunities and words such as “anticipate”,
“seek”, intend”, “believe”, “estimate”, “expect”, “project”, “plan”, or
similar phrases may be deemed “forward-looking statements” within the
meaning of the Private Securities Litigation Reform Act of 1995. Actual
results could differ from those projected in any forward-looking
statements due to numerous factors. Such factors include, among others,
the inherent uncertainties associated with new projects, the future U.S.
and global economies, the impact of competition, and the Company’s
reliance on existing regulations regarding the use and development of
cannabis-based products. These forward-looking statements are made as of
the date of this news release, and we assume no obligation to update
the forward-looking statements, or to update the reasons why actual
results could differ from those projected in the forward-looking
statements. Although we believe that any beliefs, plans, expectations
and intentions contained in this press release are reasonable, there can
be no assurance that any such beliefs, plans, expectations or
intentions will prove to be accurate. Investors should consult all of
the information set forth herein and should also refer to the risk
factors disclosure outlined in our annual report on Form 10-12G, our
quarterly reports on Form 10-Q and other periodic reports filed from
time-to-time with the Securities and Exchange Commission. For more
information, please visit www.sec.gov.
Tags: CSE, Hemp, Marijuana, stocks, tsx, tsx-v, weed Posted in All Recent Posts, Marijuana Company of America | Comments Off on Marijuana Company of America $MCOA and Joint Venture Partner Global Hemp Group Announce Start of Commercial Planting at Hemp Farm $AERO $CBDS $CGRW $APH.ca $GBLX $ACG $ACB $WEED.ca $HIP.ca
Posted by AGORACOM-JC
at 8:28 AM on Tuesday, June 18th, 2019
Tetra Natural Health, a subsidiary of Tetra Bio-Pharma (TSX VENTURE: TBP) (OTCQB: TBPMF), today announced that it has signed an exclusive agreement with Spyder Cannabis Inc. (TSX VENTURE: SPDR) to distribute the three flavors of its Hemp Energy Drink in cannabis accessory stores and vapes stores in Canada and the US
Drink is expected to be available to consumers in Spyder’s retail stores located in Scarborough, Woodbridge, Burlington, and shortly at the Niagara Falls and Pickering locations, which are expected to be opened early this summer.
OTTAWA, June 18, 2019 — Tetra Natural Health, a subsidiary of Tetra Bio-Pharma (TSX VENTURE: TBP) (OTCQB: TBPMF), today announced that it has signed an exclusive agreement with Spyder Cannabis Inc. (TSX VENTURE: SPDR) (“Spyderâ€) to distribute the three flavors of its Hemp Energy Drink in cannabis accessory stores and vapes stores in Canada and the US. The drink is expected to be available to consumers in Spyder’s retail stores located in Scarborough, Woodbridge, Burlington, and shortly at the Niagara Falls and Pickering locations, which are expected to be opened early this summer. A launch event will be held during the Canada Day long weekend at the Niagara Falls location situated at 6474 Lundys Lane.
“We are very excited to be adding the Hemp Energy Drink to our
portfolio of premium brands that will be available to our growing
clientele,†stated Daniel Pelchovitz, CEO and President of Spyder. “This
new offering will please our customers who are always seeking unique
and distinctive quality products in this emerging industry.â€
“This exclusive agreement allows us to take another step in
implementing our distribution strategy and achieving our goal of making
our Hemp Energy Drink accessible to all consumers “ said Richard
Giguère, CEO of Tetra Natural Health “Consumers appreciate the qualities
of the Hemp Energy Drink (HED) including the fact that it contains more
natural ingredients than other energy drinks, and is the first energy
drink made with hemp available in the country†adds Derek Theriault,
National Sales Director of Tetra Natural Health.
About Tetra Natural Health: Tetra Natural Health
Inc. is a subsidiary of Tetra Bio-Pharma Inc. that focuses on
identification, development and marketing of hemp or cannabis-based
natural health products, or cannabinoids-based products authorized for
sale by Health Canada. For more information, visit: www.tetranaturalhealth.com
About Spyder Cannabis Inc. Founded in 2014 Spyder
is an established chain of three high-end vape stores in Ontario, with
stores located in Woodbridge, Scarborough and Burlington. The Spyder
brand is defined by its high-quality proprietary line of e-juice,
liquids and exclusive retail deals, dispensed in uniquely designed
stores creating the optimal customer experience. Spyder is building off
this leading retail, distribution and branding eCig and vapes company
and is pursuing expansion into the legal cannabis market. Spyder has
developed a scalable retail model with an aggressive expansion plan to
create a significant retail footprint with targeted and disciplined
retail distribution strategy focusing on Canadian locations in high
traffic peripheral areas.
About Tetra Bio-Pharma: Tetra Bio-Pharma (TSX-V:
TBP) (OTCQB: TBPMF) a biopharmaceutical leader in cannabinoid-based
drug discovery and development with a Health Canada approved
and FDA reviewed clinical program aimed at bringing novel prescription
drugs and treatments to patients and their healthcare providers. Tetra
Bio-Pharma has subsidiaries engaged in the development of an advanced
and growing pipeline of Bio Pharmaceuticals, Natural Health and
Veterinary Products containing cannabis and other medicinal plant-based
elements. With patients at the core of its mission, Tetra Bio-Pharma is
focused on providing rigorous scientific validation and safety data
required for inclusion into the existing bio pharma industry by
regulators, physicians and insurance companies. For more information
visit: www.tetrabiopharma.com
Source: Tetra Bio-Pharma
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of this
release.
Forward-looking statements Some statements in
this release may contain forward-looking information. All statements,
other than of historical fact, that address activities, events or
developments that the Company believes, expects or anticipates will or
may occur in the future (including, without limitation, statements
regarding potential acquisitions and financings) are forward-looking
statements. Forward-looking statements are generally identifiable by use
of the words “may”, “will”, “should”, “continue”, “expect”,
“anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or
the negative of these words or other variations on these words or
comparable terminology. Forward-looking statements are subject to a
number of risks and uncertainties, many of which are beyond the
Company’s ability to control or predict, that may cause the actual
results of the Company to differ materially from those discussed in the
forward-looking statements. Factors that could cause actual results or
events to differ materially from current expectations include, among
other things, without limitation, the inability of the Company to obtain
sufficient financing to execute the Company’s business plan;
competition; regulation and anticipated and unanticipated costs and
delays, the success of the Company’s research and development
strategies, the applicability of the discoveries made therein, the
successful and timely completion and uncertainties related to the
regulatory process, the timing of clinical trials, the timing and
outcomes of regulatory or intellectual property decisions and other
risks disclosed in the Company’s public disclosure record on file with
the relevant securities regulatory authorities. Although the Company has
attempted to identify important factors that could cause actual results
or events to differ materially from those described in forward-looking
statements, there may be other factors that cause results or events not
to be as anticipated, estimated or intended. Readers should not place
undue reliance on forward-looking statements. While no definitive
documentation has yet been signed by the parties and there is no
certainty that such documentation will be signed The forward-looking
statements included in this news release are made as of the date of this
news release and the Company does not undertake an obligation to
publicly update such forward-looking statements to reflect new
information, subsequent events or otherwise unless required by
applicable securities legislation.
Tags: CSE, Hemp, Marijuana, stocks, tsx, tsx-v, weed Posted in Spyder Cannabis Inc. | Comments Off on New #Hemp Energy Drink to be offered to consumers in #cannabis accessory stores, #vapes stores, and kiosks in Canada and the US #Spyder $SPDR.ca $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $TRST.ca $OGI.ca
Posted by AGORACOM-JC
at 7:15 AM on Tuesday, June 18th, 2019
Announced the launch of new clinic brand Sun Valley Health and the launch of a nationwide clinic franchise program. http://www.sunvalleyhealth.com
Company is consolidating its clinic operations under one consistent brand, merging the existing clinic operations of Sun Valley Clinics in Arizona and Nevada, plus the existing physical and mobile clinic operations of Empower Clinics in Washington State and Oregon State
VANCOUVER, June 18, 2019 –EMPOWER CLINICS INC. (CSE: CBDT) (Frankfurt 8EC) (“Empower” or the “Company“), a vertically integrated and growth-oriented CBD life sciences company, and a multi-state operator of medical health & wellness clinics, is pleased to announce the launch of our new clinic brand Sun Valley Health and the launch of a nationwide clinic franchise program. http://www.sunvalleyhealth.com
The Company is consolidating its clinic operations under one
consistent brand, merging the existing clinic operations of Sun Valley
Clinics in Arizona and Nevada, plus the existing physical and mobile clinic operations of Empower Clinics in Washington State and Oregon State.
All Company clinics will commence operating under Sun Valley Health,
with the updated brand changes coming into effect immediately.
The Company is also announcing the official launch of the Sun Valley
Health franchise program. With the 2019 Franchise Disclosure Document
(FDD) ready to deploy and the 2019 franchise audit completed, the
Company will be in a position to accept applications for a Sun Valley
Health franchise throughout the United States.
Investment has already been made in developing a new trade show
booth, plus new franchise sales & marketing material that will be
utilized to showcase the franchise opportunity at industry specific and
franchise trade shows throughout North America. The new
website is live and will continue to be developed, adding content and
features for patients, consumers and prospective franchisees.
Nine (9) trade shows have already been booked over the next nine months, with the first show taking place in St. Louis, MO July 23rd & 24th, 2019. Look for us at booth #144 at https://www.cannabisimp.com/st-louis-expo/
“At Sun Valley Health, we’ve taken the once cumbersome process of
obtaining lab tested, all natural CBD and health supplements, into a
clinical professional experience.” said Dustin Klein,
Empowers SVP, Business Development and Director. “We provide alternative
health modalities and products backed by science, that pass our
rigorous standards of quality and effectiveness.”
HIGHLIGHTS
Scientific Approach to Alternative Medicine Having
access to physicians that understand qualifying conditions of patients
is a primary focus of our entire team. Care for each individual’s
circumstance and need guides our staff protocols on privacy, care and
treatment options.
Know What’s in your Product The products offered to our
patients in clinics and online, go though rigorous testing standards by
independent labs to ensure, what’s represented on the label is correct.
“Knowing what’s in your product is about trust, and professionalism counts, standards count and testing counts,” said Steven McAuley,
CEO of Empower. “Our Sollievo product line and any product line that we
choose to include in our clinic kiosks, online or are offered through
franchise operations, will be subject to testing and must meet the
highest of standards.”
ABOUT EMPOWER
Empower is a leading multi-state operator of a network of
physician-staffed clinics focused on helping patients improve and
protect their health through innovative physician recommended treatment
options. Operating as a vertically-integrated health & wellness
brand with it’s first hemp-derived CBD extraction facility under
development, the Company can produce and package its proprietary line of
cannabidiol (CBD) based products and distribute through company owned
and franchised clinics, with wholesale partnerships, online and with
retailers nationwide.
ON BEHALF OF THE BOARD OF DIRECTORS:
Steven McAuley Chief Executive Officer
DISCLAIMER FOR FORWARD-LOOKING STATEMENTS
This news release contains certain “forward-looking statements”
or “forward-looking information” (collectively “forward looking
statements”) within the meaning of applicable Canadian securities laws. All
statements, other than statements of historical fact, are
forward-looking statements and are based on expectations, estimates and
projections as at the date of this news release. Forward-looking statements
can frequently be identified by words such as “plans”, “continues”,
“expects”, “projects”, “intends”, “believes”, “anticipates”,
“estimates”, “may”, “will”, “potential”, “proposed” and other similar
words, or information that certain events or conditions “may” or “will”
occur. Forward-looking statements in this news release include
statements regarding; the Company’s intention to open a hemp-based CBD
extraction facility, the expected benefits to the Company and its
shareholders as a result of the proposed acquisitions and partnerships;
the terms of the proposed acquisitions and partnerships; the
effectiveness of the extraction technology; the expected benefits for
Empower’s patient base and customers; access to Empower’s home delivery
and e-commerce platform; the benefits of CBD based products; the effect
of the approval of the Farm Bill; the growth of the Company’s patient
list and that the Company will be positioned to be a market-leading
service provider for complex patient requirements in 2019 and beyond.
Such statements are only projections, are based on assumptions known to
management at this time, and are subject to risks and uncertainties that
may cause actual results, performance or developments to differ
materially from those contained in the forward-looking statements,
including; that the Company may not open a hemp-based CBD extraction
facility; that the hemp-based CBD extraction facility may not be fully
operation by Q2 2019 if at all; that legislative changes may have an
adverse effect on the Company’s business and product development; that
the Company may not be able to obtain adequate financing to pursue its
business plan; general business, economic, competitive, political and
social uncertainties; failure to obtain any necessary approvals in
connection with the proposed acquisitions and partnerships; and other
factors beyond the Company’s control. No assurance can be given that any
of the events anticipated by the forward-looking statements will occur
or, if they do occur, what benefits the Company will obtain from them.
Readers are cautioned not to place undue reliance on the forward-looking
statements in this release, which are qualified in their entirety by
these cautionary statements. The Company is under no obligation, and
expressly disclaims any intention or obligation, to update or revise any
forward-looking statements in this release, whether as a result of new
information, future events or otherwise, except as expressly required by
applicable laws.
CONTACTS: Investors: Steve Low, Boom Capital Markets, [email protected], 647-620-5101; Investors: Steven McAuley, CEO, [email protected], 604-789-2146; For French inquiries: Remy Scalabrini, Maricom Inc., E: [email protected], T: (888) 585-MARICopyright CNW Group 2019
Tags: CSE, Hemp, Marijuana, stocks, tsx, tsx-v, weed Posted in Empower Clinics Inc. | Comments Off on Empower Clinics $CBDT.ca Launches Sun Valley Health and National Franchise Program $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $TRST.ca $OGI.ca
Posted by AGORACOM-JC
at 8:41 AM on Thursday, June 13th, 2019
Further to the Israeli sponsorship research agreement announced in the Company’s news release dated May 14, 2019, management is pleased to announce that it has paid a 10% deposit to ESEV R&D to begin the formulations process on the water soluble cannabis-based (CBD) supplement energy drink
The final report will include; clinical trials results, sourcing of ingredients, PH balance, nutritional chart, shelf-life, as well as cost of ingredients and contacts.
VANCOUVER, British Columbia, June 13, 2019 – BOUGAINVILLE VENTURES INC. (“Bougainville” or the “Company”) (CSE:BOG) (Frankfurt:8BV)Further to the Israeli sponsorship research agreement announced in the Company’s news release dated May 14, 2019, management is pleased to announce that it has paid a 10% deposit to ESEV R&D to begin the formulations process on the water soluble cannabis-based (CBD) supplement energy drink. The final report will include; clinical trials results, sourcing of ingredients, PH balance, nutritional chart, shelf-life, as well as cost of ingredients and contacts.
Andy Jagpal, President, Comments:“We
have already begun sourcing a local bottling company to handle the
production and processing of the CBD energy drink once the formulations
are ready. We are adamant about bringing the energy drink formulation to
market and feel we have developed the right relationships to get the
job done right.â€
WORMCASTING TRANSACTION FINANCING UPDATE
Further to the Company news release dated June 11, 2019, management
is pleased to announce that it has paid-off the final outstanding
payment of USD$120,000 owed to Worm Castings Farms Inc. pursuant to
Bougainville’s obligation under the Worm Castings Share Exchange
Agreement.
OROVILLE CAMPUS UPDATE
Further to the Company news release dated April 1, 2019, management
would like to announce that the tenant grower is waiting to receive
final occupancy approval from the Washington State Liquor and Cannabis
Board (“WSLCBâ€) to begin planting. The tenant expects a visit to the
site by the WSLC in the near future and is planning to plant a 20,000
sq. ft. out-door crop.
In addition, the Company wishes to correct an error in its news
release dated May 1, 2019 in which the Company announced that a private
placement with gross proceeds of $190,000 for 3,166,666 Units at a price
of $0.06 per Unit (the “Private Placementâ€) had closed. The Private
Placement was oversubscribed for 3,316,666. The remainder of the news
release dated May 1, 2019 is accurate and the oversubscribed Private
Placement was closed on May 1, 2019 with the amount of $199,000 for
3,316,666 Units
About Bougainville Ventures, Inc. Bougainville
Ventures Inc. is dedicated to rapid growth in production, processing,
retail and branding of cannabis and cannabis related products. Currently
the company provides strategic capital to the thriving cannabis
cultivation sector through ownership and development of commercial real
estate properties. We offer fully built out turnkey facilities equipped
with state-of-the-art growing infrastructure to cannabis growers and
processors. Also, the Company is focused on building a strong presence
in the hemp industry with the objective of extracting cannabinoids (CBD
& CBN) in both Canada and the United States. With our flagship Hemp
project in Oregon State the Company has proprietary, patent-pending hemp
root oil extraction technology and formulas for cannabis topicals and
tinctures.
http://bougainvilleinc.com/
On behalf of the Board of Directors BOUGAINVILLE VENTURES INC.
Andy Jagpal, CEO and Director
For further information, please contact Andy Jagpal at [email protected] or 1-888-395-7816
FORWARD LOOKING STATEMENTS: This news release contains certain
forward-looking statements within the meaning of Canadian securities
laws. Forward-looking statements are based on the expectations and
opinions of the Company’s management on the date the statements are
made. The assumptions used in the preparation of such statements,
although considered reasonable at the time of preparation, may prove to
be imprecise and, as such, undue reliance should not be placed on
forward-looking statements. The Company expressly disclaims any
intention or obligation to update or revise any forward-looking
statements whether as a result of new information, future events or
otherwise.
No regulatory authority has approved or disapproved the information contained in this news release.
Posted by AGORACOM-JC
at 7:12 AM on Thursday, June 13th, 2019
Company continues to reach a number of important milestones on its path forward, as a global health and wellness company, serving the needs of patients through its network of physician-staffed health and pain management clinics, formulating CBD based products and developing its first CBD extraction facility
VANCOUVER, June 13, 2019 – EMPOWER CLINICS INC. (CSE: CBDT) (Frankfurt 8EC) (“Empower” or the “Company“), a vertically integrated and growth-oriented CBD life sciences company, and a multi-state operator of medical health & wellness clinics, is pleased to provide an update on recent corporate activities and Director changes.
The Company continues to reach a number of important milestones on
its path forward, as a global health and wellness company, serving the
needs of patients through its network of physician-staffed health and
pain management clinics, formulating CBD based products and developing
its first CBD extraction facility.
HIGHLIGHTS
Takes Possession of CBD Extraction Facility As previously announced, the Company has taken possession of its new facility in greater Portland, Oregon
that will be home to a fully functioning hemp-based CBD extraction
facility, with the first extraction system expected to have the capacity
to produce 6,000 kilograms of extracted product per year. The facility
is expected to provide Empower with vertical integration into the CBD
supply chain, producing isolates, distillates and winterized oil that
are showing strong demand in local and national markets. The Company has
commenced preliminary build-out starting with IT and technology
implementations plus security system installations.
Engages Leading Architect Firm Empower has engaged Pathangay Architects www.pathangayarchitects.com of Phoenix, AZ
lead by Navin Pathangay as the lead architect firm for the build-out of
the first company extraction facility. Navin Architects are one of the
leading Cannabis industry architects having worked on numerous industry
projects including dispensaries, medical clinics, grow operations and
extraction facilities.
Integration of Sun Valley Clinics The Sun Valley
Clinics acquisition is providing productivity gains and in-market
expertise that is accretive to our clinic division. Official operational
integration is fully underway, with the best practices of Sun Valley and Empower are coming together to create world-class clinic operations. The operations team at Sun Valley
has assumed key administrative tasks on behalf of the Empower network
of clinics including bookkeeping, human resources, payroll and
day-to-day accounts payable and accounts receivable tasks.
We expect to drive further productivity by eliminating duplicate
and/or redundant information technology systems and by brining campaign
marketing programs such as text messaging, email and call center
functions under the Sun Valley operations, to improve effectiveness and reduce costs.
The current Sun Valley clinic locations are as follows:
4218 W Dunlap Ave, Phoenix, AZ 12801 W Bell Rd #145, Surprise, AZ 4015 E Bell Rd #130, Phoenix, AZ 2011 E University Dr, Mesa, AZ 7074 E Speedway Blvd, Tucson, AZ 2550 S Rainbow Blvd, Las Vegas, NV
Launches CBD Tincture Product Line Empower has
commenced selling its proprietary line of CBD-based products called
SOLLIEVO, through its network of company-owned clinics in the United States. The Sollievo tincture line includes four (4) preliminary SKU’s for chronic pain, insomnia, digestion and anxiety. Preliminary
user feedback has been positive and third party lab test results have
confirmed the ingredients and dosages of our proprietary formulations
are consistent with what is indicated on the labels and packaging.
Empower’s patient base and customers are expected to benefit from access
to high margin derivative products, including CBD lotion, tinctures,
spectrum oils, capsules, lozenges, patches, e-drinks, topical lotions,
gel caps, hemp extract drops and pet elixir hemp extract drops.
CBD Market Demand The passing in the United States of the US$867 billion Agriculture Improvement Act (the “Farm Bill“)
has legalized hemp and hemp-based products. This has created an
opportunity for the production and sale of a variety of CBD-based
products that can provide genuine help and effective relief to millions
of people suffering from a variety of qualifying conditions. Recent
reports and studies indicate the approval of the Farm Bill could create a
US$20 billion industry by 2022.
“With the closing of the Sun Valley Clinics acquisition behind us, we
are already seeing such positive impact with integration and the
development of our overall company culture,” said Steven McAuley,
CEO of Empower. “By adding the extra resources to our company, we have
much more capacity grow and execute on the various initiatives I have
announced previously.”
Appointment of New Board Member
The Company is also pleased to announce the appointment of Mr. Andrejs Bunkse as a Director of the company, effective as of May 26, 2019. Mr. Bunkse is a graduate of Syracuse University and holds a Juris Doctorate from Santa Clara University
School of Law. As the owner and practicing attorney of Rain Legal and
partner in Nimbus Legal, Andy brings industry specific expertise and
deep connections to major industry players plus the investment banking
and Family office community.
“We are so honored to have Andy Bunkse join our Board, to play an
active role in supporting our next phase of growth and development”,
said Steven McAuley, CEO of Empower. “His substantial
negotiating and deal structuring experience along with industry ties and
reputation, adds tremendous pedigree to our leadership team.”
The Company also announces the resignation of Peter McDonough as a Director effective May 24th, 2019. We would like to thank Peter for his contributions.
ABOUT EMPOWER
Empower is a leading multi-state operator of a network of
physician-staffed clinics focused on helping patients improve and
protect their health through innovative physician recommended treatment
options. Operating as a vertically-integrated health & wellness
brand with it’s first hemp-derived CBD extraction facility under
development, the Company can produce and package its proprietary line of
cannabidiol (CBD) based products and distribute through company owned
and franchised clinics, with wholesale partnerships, online and with
retailers nationwide.
ON BEHALF OF THE BOARD OF DIRECTORS:
Steven McAuley Chief Executive Officer
DISCLAIMER FOR FORWARD-LOOKING STATEMENTS
This news release contains certain “forward-looking statements”
or “forward-looking information” (collectively “forward looking
statements”) within the meaning of applicable Canadian securities laws. All
statements, other than statements of historical fact, are
forward-looking statements and are based on expectations, estimates and
projections as at the date of this news release. Forward-looking statements
can frequently be identified by words such as “plans”, “continues”,
“expects”, “projects”, “intends”, “believes”, “anticipates”,
“estimates”, “may”, “will”, “potential”, “proposed” and other similar
words, or information that certain events or conditions “may” or “will”
occur. Forward-looking statements in this news release include
statements regarding; the Company’s intention to open a hemp-based CBD
extraction facility, the expected benefits to the Company and its
shareholders as a result of the proposed acquisitions and partnerships;
the terms of the proposed acquisitions and partnerships; the
effectiveness of the extraction technology; the expected benefits for
Empower’s patient base and customers; access to Empower’s home delivery
and e-commerce platform; the benefits of CBD based products; the effect
of the approval of the Farm Bill; the growth of the Company’s patient
list and that the Company will be positioned to be a market-leading
service provider for complex patient requirements in 2019 and beyond.
Such statements are only projections, are based on assumptions known to
management at this time, and are subject to risks and uncertainties that
may cause actual results, performance or developments to differ
materially from those contained in the forward-looking statements,
including; that the Company may not open a hemp-based CBD extraction
facility; that the hemp-based CBD extraction facility may not be fully
operation by Q2 2019 if at all; that legislative changes may have an
adverse effect on the Company’s business and product development; that
the Company may not be able to obtain adequate financing to pursue its
business plan; general business, economic, competitive, political and
social uncertainties; failure to obtain any necessary approvals in
connection with the proposed acquisitions and partnerships; and other
factors beyond the Company’s control. No assurance can be given that any
of the events anticipated by the forward-looking statements will occur
or, if they do occur, what benefits the Company will obtain from them.
Readers are cautioned not to place undue reliance on the forward-looking
statements in this release, which are qualified in their entirety by
these cautionary statements. The Company is under no obligation, and
expressly disclaims any intention or obligation, to update or revise any
forward-looking statements in this release, whether as a result of new
information, future events or otherwise, except as expressly required by
applicable laws.
Posted by AGORACOM-JC
at 9:12 AM on Tuesday, June 11th, 2019
Will be opening an additional two retail stores within the next month, for a total of 5 locations, and the upcoming launch of its proprietary SPDR website
Commences trading today on the TSX Venture Exchange,
Under phase one of the Turn-Key Strategy, Spyder intends to operate a number of retail locations that will, in contrast to a number of its competitors, generate revenue by operating as retailers of a variety of non-cannabis products
Under phase two of the Turn-Key Strategy, Spyder will, subject to the receipt of cannabis retail licences from the Alcohol and Gaming Commission of Ontario and the Alberta Gaming, Liquor and Cannabis Commission, convert these retailers into cannabis stores at the earliest possible opportunity
Vaughan, Ontario–(June 11, 2019) – Spyder Cannabis Inc. (TSXV: SPDR) (“Spyder” or the “Company“), an established Ontario retail operator, is pleased to announce that it will be opening an additional two retail stores within the next month (the “NewRetail Locations“), for a total of 5 locations, and the upcoming launch of its proprietary SPDR website (the “SPDR Website“). The Company, which commences trading today on the TSX Venture Exchange, believes that the Retail Locations and the SDPR Website are a valuable part of its North American retail and e-commerce wellness growth strategy.
Retail Locations
The Company will open the New Retail Locations within the next month,
which will be located in Niagara Falls at 6474 Lundys Lane (the “Lundys Lane Location“)
and in Pickering at 776 Liverpool Road, Unit 4. The New Retail
Locations will, initially, focus on the sale of cannabis accessories,
hemp seed oil products, and hemp accessories.
The Lundys Lane Location, two other retail locations that Spyder
operates in Burlington and Calgary and a location that it intends to
open in Guelph, subject to negotiating satisfactory terms with the
landlord, will all be converted into cannabis retail stores as part of
the Company’s “Cannabis Turn-Key Strategy” (the “Turn-Key Strategy“).
Under phase one of the Turn-Key Strategy, Spyder intends to operate a
number of retail locations that will, in contrast to a number of its
competitors, generate revenue by operating as retailers of a variety of
non-cannabis products. Under phase two of the Turn-Key Strategy, Spyder
will, subject to the receipt of cannabis retail licences from the
Alcohol and Gaming Commission of Ontario and the Alberta Gaming, Liquor
and Cannabis Commission, convert these retailers into cannabis stores at
the earliest possible opportunity. The Company believes this strategy
will allow it to generate stable revenue streams during the interim
period before the stores receive a retail cannabis licence, and will
allow the Company to swiftly pivot into the sale of cannabis products
once appropriate licences have been received.
SPDR Website
The Company expects to launch the SPDR Website by July 1, 2019. The
SPDR Website is currently in an advanced stage of development, and will
focus on selling cannabis accessories and a variety of hemp-based
products on a retail and wholesale basis within Canada. The Company
intends to focus on offering its own SPDRTM branded products, which are
made up of a number top-of-the line and unique products, along with
leveraging the Company’s deep knowledge of the retail industry to offer a
number of other best-in-class products that it has identified over the
years.
“Spyder is excited to be able to announce our pending opening of two
additional retail locations within Ontario, bringing our total to 5
operating stores and the launch of the SPDR website, which we believe
demonstrate our commitment to creating value for our shareholders, a
responsibility we take seriously as a newly listed company. We recently
promised that we would take tangible steps to benefit our shareholders,
and we believe that these latest developments leave us headed in the
right direction,” said Dan Pelchovitz, Chief Executive Officer and
President of Spyder.
About Spyder
Founded in 2014 Spyder is an established chain of three high-end vape
stores in Ontario, with stores located in Woodbridge, Scarborough and
Burlington. The Spyder brand is defined by its high-quality proprietary
line of e-juice, liquids and exclusive retail deals, dispensed in
uniquely designed stores creating the optimal customer experience.
Spyder is building off this leading retail, distribution and branding
eCig and vapes company and is pursuing expansion into the legal cannabis
market. Spyder has developed a scalable retail model with aggressive
expansion plan to create a significant retail footprint with targeted
and disciplined retail distribution strategy focusing on Canadian
locations in high traffic peripheral areas.
Cautionary Statements
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of this
release.
This news release includes statements containing certain
“forward-looking information” within the meaning of applicable
securities laws (“forward-looking statements”). Forward-looking
statements are frequently characterized by words such as “plan”,
“continue”, “expect”, “project”, “intend”, “believe”, “anticipate”,
“estimate”, “may”, “will”, “potential”, “proposed” and other similar
words, or statements that certain events or conditions “may” or “will”
occur. In particular, this news release contains forward looking
statements regarding, without limitation: Spyder’s anticipated roll-out
of the New Retail Locations and the SPDR Website in the timelines
indicated or at all, the receipt by Spyder of cannabis licences on the
timelines indicated or at all, and the products that Spyder plans to
offer at the New Retail Locations and the SPDR Website.
Posted by AGORACOM-JC
at 7:18 AM on Tuesday, June 11th, 2019
Signed a letter of intent (LOI) to provide funding and to acquire 100% of the assets and inventory of Island Biopharma Inc.
Biopharma has developed a dedicated line of Cannabidiols products which a include proprietary CBD blended tincture product with three specific recipes for anxiety, energy and sleep.
VANCOUVER, British Columbia, June 11, 2019 — BOUGAINVILLE VENTURES INC. (“Bougainville” or the “Company”) (CSE:BOG) is pleased to announce that it has signed a letter of intent (LOI) to provide funding and to acquire 100% of the assets and inventory of Island Biopharma Inc.(Biopharma). Biopharma has developed a dedicated line of Cannabidiols (“CBDâ€) products which a include proprietary CBD blended tincture product with three specific recipes for anxiety, energy and sleep.
LOI Terms
Subject to Board approval from the Company and completion of
satisfactory due diligence, the parties intend to enter into a
definitive agreement on or before June 30, 2019. The Company will
acquire 100% of Biopharma assets and current inventory. The
consideration is to be payable in such number of common shares in its
share capital (“Consideration Shares”) at a per share price equal to the
volume weighted average price of such shares on the Canadian Securities
Exchange over a 15-day period ending on the day such Consideration
Shares are required to be issued (“15 day VWAP”). In addition, Biopharma
will contribute operational expertise, exclusive licenses for products
marketed in North America supported by an intellectual property
licensing agreement, and exclusivity for all current and future
technology for oil extraction in North America. The final evaluation
will be determined by an independent third party evaluator, which is
currently in progress.
Assets include:
Proprietary Formulas for Anxiety, Energy and Sleep
Lab Reports
All Proprietary Information
About Island Biopharma Inc.
Biopharma possesses a CBD blended tincture product with three
specific recipes for anxiety, energy and sleep. The philosophy of
Biopharma is to create products using the highest quality of bio-active
ingredients, and oil extraction methods that preserve the essence of the
cannabis plant. Biopharma has studied plant genetics for their
therapeutic effects by incorporating modern research techniques and by
analyzing the healing and therapeutic benefits of each strain giving the
company a huge range of combinations and therapeutic benefits for
specific ailments.
According to an estimate from cannabis
industry analysts the hemp-CBD market alone could hit $22 billion by
2022. CBD can be used to effectively treat epilepsy, anxiety, insomnia
and chronic pain. The Island Biopharma CBD line is designed to harness
the healing power of cannabis without the psychotropic effects of
tetrahydrocannabinol (“THCâ€).
CEO, Andy Jagpal Comments: “This marks an
exciting step forward for our brand’s expansion into multiple CBD
products. The acquisition of Island Biopharma will contribute greatly to
our future product lines. With the development of our CBD infused
energy drink already in development this acquisition will complement our
goal of producing high quality proven cannabaniod products. This is
in-line with the anticipated launch of the Canadian cannabis legislation
bringing about the legalization of the edible market slated for the
fall of 2019â€.
WORMCASTING TRANSACTION FINANCING UPDATE
Further to the Form 45-102F1 Notice of Intention to Distribute
Securities filed May 22, 2019 and associated news release dated May 24,
2019 the Company announces that management has sold a total of 1,000,000
shares of (BOG:CSE) with proceeds of $CAD100,000. These proceeds have
been contributed towards the final outstanding payment of $USD120,000
owed to Worm Castings pursuant to Bougainville’s obligation under the
Worm Castings Transaction announced in the Company’s news release dated
May 23, 2019. Management continues to defer salaries as it has for the
past two years to help conserve working capital to enable the company to
reach its milestones.
About Bougainville Ventures, Inc. Bougainville
Ventures Inc. is dedicated to rapid growth in production, processing,
retail and branding of cannabis and cannabis related products. Currently
the company provides strategic capital to the thriving cannabis
cultivation sector through ownership and development of commercial real
estate properties. We offer fully built out turnkey facilities equipped
with state-of-the-art growing infrastructure to cannabis growers and
processors. Also, the Company is focused on building a strong presence
in the hemp industry with the objective of extracting cannabinoids (CBD
& CBN) in both Canada and the United States. With our flagship Hemp
project in Oregon State the Company has proprietary, patent-pending hemp
root oil extraction technology and formulas for cannabis topicals and
tinctures.
http://bougainvilleinc.com/
On behalf of the Board of Directors BOUGAINVILLE VENTURES INC.
Andy Jagpal, CEO and Director
For further information, please contact Andy Jagpal at [email protected] or 1-844-734-8420
FORWARD LOOKING STATEMENTS: This news release contains certain
forward-looking statements within the meaning of Canadian securities
laws. Forward-looking statements are based on the expectations and
opinions of the Company’s management on the date the statements are
made. The assumptions used in the preparation of such statements,
although considered reasonable at the time of preparation, may prove to
be imprecise and, as such, undue reliance should not be placed on
forward-looking statements. The Company expressly disclaims any
intention or obligation to update or revise any forward-looking
statements whether as a result of new information, future events or
otherwise.
No regulatory authority has approved or disapproved the information contained in this news release.
Source: GlobeNewswire (June 11, 2019 – 3:00 AM EDT)
Tags: CBD, Hemp, Marijuana, stocks, tsx, tsx-v, weed Posted in Bougainville Ventures | Comments Off on Bougainville Ventures Inc. $BOG.ca Enters in to Funding and Asset Purchase Agreement with Island Biopharma Inc. $CROP.ca $VP.ca NF.ca $MCOA
Posted by AGORACOM-JC
at 9:43 AM on Monday, June 10th, 2019
Joining us on this episode is Peter P. Swistak, President/CEO of Vertical Exploration.
The company has recently received positive results from its Phase 1
Research and Development program that was conducted by AGRINOVA using
wollastonite from the Company’s St-Onge deposit. All of the research and
testing in the Phase 1 program was managed and monitored by AGRINOVA, a
highly-regarded Center for Research and Innovation in Agriculture in
Quebec, in an effort to optimize the potential agricultural uses of
wollastonite and help improve production methods for farmers and
agricultural companies located in Quebec.